Fig. 2.
The mean (SD) percentage of sputum eosinophils before and after an inhaled corticosteroid (budesonide) and a leukotriene antagonist (montelukast) before and following an allergen inhalation challenge. There was a subsequent reduction in the allergen-induced eosinophilia in the presence of all treatments.
*Indicates significant difference from pre-allergen value in the same treatment group. Filled triangles indicate a significant difference from placebo at the same time point.49